170 related articles for article (PubMed ID: 31106706)
21. Systemic treatments in childhood psoriasis: a French multicentre study on 154 children.
Charbit L; Mahé E; Phan A; Chiaverini C; Boralevi F; Bourrat E; Lasek A; Maruani A; Aubin F; Droitcourt C; Barbarot S; Mallet S; Mazereeuw-Hautier J; Begon E; Abasq C; Plantin P; Souillet AL; Hadj-Rabia S; Bursztejn AC;
Br J Dermatol; 2016 May; 174(5):1118-21. PubMed ID: 26617180
[No Abstract] [Full Text] [Related]
22. Invasive fungal infections in pediatric patients treated with tumor necrosis alpha (TNF-α) inhibitors.
Tragiannidis A; Kyriakidis I; Zündorf I; Groll AH
Mycoses; 2017 Apr; 60(4):222-229. PubMed ID: 27766695
[TBL] [Abstract][Full Text] [Related]
23. Polymorphisms associated with adalimumab and infliximab response in moderate-to-severe plaque psoriasis.
Ovejero-Benito MC; Prieto-Pérez R; Llamas-Velasco M; Muñoz-Aceituno E; Reolid A; Saiz-Rodríguez M; Belmonte C; Román M; Ochoa D; Talegón M; Cabaleiro T; Daudén E; Abad-Santos F
Pharmacogenomics; 2018 Jan; 19(1):7-16. PubMed ID: 29192552
[TBL] [Abstract][Full Text] [Related]
24. Treatment of canine atopic dermatitis with cyclosporine: a pilot clinical study.
Fontaine J; Olivry T
Vet Rec; 2001 May; 148(21):662-3. PubMed ID: 11400987
[No Abstract] [Full Text] [Related]
25. Safety of long-term treatment with cyclosporin A in resistant chronic plaque psoriasis: a retrospective case series.
García-Bustínduy M; Escoda M; Guimerá FJ; Sáez M; Dorta S; Fagundo E; Sánchez-González R; Noda-Cabrera A; García-Montelongo R
J Eur Acad Dermatol Venereol; 2004 Mar; 18(2):169-72. PubMed ID: 15009296
[TBL] [Abstract][Full Text] [Related]
26. The FDA guidelines for the treatment of psoriasis using cyclosporine A: are they adequate?
Zackheim HS
Cutis; 2002 Nov; 70(5):288-90. PubMed ID: 12469783
[TBL] [Abstract][Full Text] [Related]
27. Advances in psoriasis therapy.
Koo J; Nguyen Q; Gambla C
Adv Dermatol; 1997; 12():47-72; discussion 73. PubMed ID: 8973735
[No Abstract] [Full Text] [Related]
28. Switching from etanercept to adalimumab is effective and safe: results in 30 patients with psoriasis with primary failure, secondary failure or intolerance to etanercept.
Van Lümig PP; Lecluse LL; Driessen RJ; Spuls PI; Boezeman JB; van de Kerkhof PC; De Jong EM
Br J Dermatol; 2010 Oct; 163(4):838-46. PubMed ID: 20649798
[TBL] [Abstract][Full Text] [Related]
29. Cyclosporine: what clinicians need to know.
Koo J; Lee J
Dermatol Clin; 1995 Oct; 13(4):897-907. PubMed ID: 8785893
[TBL] [Abstract][Full Text] [Related]
30. Use of basiliximab as a cyclosporin-sparing agent in palmoplantar pustular psoriasis with myalgia as an adverse effect.
Bell HK; Parslew RA
Br J Dermatol; 2002 Sep; 147(3):606-7. PubMed ID: 12207613
[No Abstract] [Full Text] [Related]
31. Sinecatechins 10% ointment for genital warts: Case report of a beneficial reaction in an HIV-positive woman.
Bilenchi R; Campoli M; Trovato E; Cinotti E; Rubegni P; Fimiani M
Int J STD AIDS; 2018 Sep; 29(10):1033-1035. PubMed ID: 29621948
[TBL] [Abstract][Full Text] [Related]
32. Nodular melanoma arising in a patient treated with anti-tumor necrosis factor alpha antagonists.
Carlesimo M; La Pietra M; Arcese A; Di Russo PP; Mari E; Gamba A; Orsini D; Camplone G
Int J Dermatol; 2012 Oct; 51(10):1234-6. PubMed ID: 22416995
[No Abstract] [Full Text] [Related]
33. Real world experience using Ciclosporin in psoriasis: Efficacy and toxicity in the Australasian Psoriasis Registry.
Berry W; Daniel BS; Baker C; Foley P
Australas J Dermatol; 2020 Nov; 61(4):380-382. PubMed ID: 32367517
[No Abstract] [Full Text] [Related]
34. Pharmacy costs of specialty medications for plaque psoriasis in the United States.
Yang EJ; Beck KM; Sekhon S; Bhutani T
J Am Acad Dermatol; 2019 Jan; 80(1):274-275. PubMed ID: 29673778
[No Abstract] [Full Text] [Related]
35. Development of human papillomavirus-associated Buschke-Löwenstein penile carcinoma during cyclosporine therapy for generalized pustular psoriasis.
Piepkorn M; Kumasaka B; Krieger JN; Burmer GC
J Am Acad Dermatol; 1993 Aug; 29(2 Pt 2):321-5. PubMed ID: 8393464
[TBL] [Abstract][Full Text] [Related]
36. Successful treatment of severe psoriasis with basiliximab, an interleukin-2 receptor monoclonal antibody.
Owen CM; Harrison PV
Clin Exp Dermatol; 2000 May; 25(3):195-7. PubMed ID: 10844492
[TBL] [Abstract][Full Text] [Related]
37. Antinuclear antibody formation following administration of anti-tumor necrosis factor agents in Japanese patients with psoriasis.
Yanaba K; Umezawa Y; Honda H; Sato R; Chiba M; Kikuchi S; Asahina A; Nakagawa H
J Dermatol; 2016 Apr; 43(4):443-4. PubMed ID: 26662275
[No Abstract] [Full Text] [Related]
38. Cyclosporine treatment of psoriatic erythroderma complicated by bacterial sepsis.
Sprecher E; Bergman R; Friedman-Birnbaum R
J Eur Acad Dermatol Venereol; 1999 Mar; 12(2):197-8. PubMed ID: 10343966
[No Abstract] [Full Text] [Related]
39. [Systemic therapy of psoriasis].
Altmeyer P; Nüchel C
Dtsch Med Wochenschr; 1996 Dec; 121(51-52):1605-7. PubMed ID: 9011488
[No Abstract] [Full Text] [Related]
40. Melanocytic nevus count and dermoscopic features do not differ in psoriatic patients undergoing biological agent versus conventional drug therapy.
Pirmit S; Onsun N; Su O; Ozkaya DB
G Ital Dermatol Venereol; 2017 Apr; 152(2):126-131. PubMed ID: 28166613
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
